<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02294396</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-112</org_study_id>
    <nct_id>NCT02294396</nct_id>
  </id_info>
  <brief_title>Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.</brief_title>
  <official_title>Postmarketing Study of Mirabegron in Japan: Long-term Add-on Therapy With Antimuscarinics in Patients With Overactive Bladder Treated With Mirabegron</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study was to evaluate the safety and efficacy of add-on therapy with
      anticholinergics in patients with OAB on mirabegron.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a multicenter, open-label study to evaluate the safety and efficacy of add-on
      therapy with antimuscarinics in patients with OAB treated with mirabegron.

      The total duration of the study period was 54 weeks in total, comprising a 2-week screening
      period and a 52-week treatment period. Patients who met the eligibility criteria for
      provisional enrollment received orally the study drug for the screening period (mirabegron 50
      mg) once daily after breakfast for 2 weeks. Patients who met the eligibility criteria after
      the screening period were randomized to solifenacin 5 mg, propiverine 20 mg, imidafenacin 0.2
      mg or tolterodine 4 mg in a 1:1:1:1 ratio, and received orally mirabegron 50 mg and
      antimuscarinics for 52 weeks. At week 8 visit, the dose of all antimuscarinics except for
      tolterodine could be increased by 2-fold (solifenacin 10 mg, propiverine 40 mg or
      imidafenacin 0.4 mg) if a patient met the following criteria: (1) had no response to the
      study drugs; (2) was considered by the investigator to have no safety concerns; and (3)
      agreed to increase the dose. However, in the event of AEs after the dose was increased, it
      could be reduced to the level before the increase. A dose increase for a second time after
      dose reduction was not permitted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2014</start_date>
  <completion_date type="Actual">September 7, 2016</completion_date>
  <primary_completion_date type="Actual">September 7, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From first dose of study drug up to week 52</time_frame>
    <description>TEAEs were defined as AEs observed after the first administration of the study drugs for the treatment period. The investigator assessed the severity of AEs, including abnormal clinical laboratory values, electrocardiogram (ECG), vital signs, as follows: Mild: No disruption of normal daily activities; Moderate: Affected normal daily activities; Severe: Inability to perform daily activities. A drug-related TEAE was a TEAE with at least a possible relationship to the study drug as assessed by the investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Overactive Bladder Symptom Score (OABSS) Total Score</measure>
    <time_frame>Baseline and week 4, 8, 12, 16, 28 and 52</time_frame>
    <description>The OABSS questionnaire was a questionnaire completed by participants with 4 questions regarding their OAB symptoms. For each participant, the OABSS total score was calculated from the sum total of the score of each question. The total score ranges from 0 to 15 with higher score indicating more symptoms. The OABSS data obtained at week 0 were used as baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved Normalization for OABSS Total Score</measure>
    <time_frame>Week 52 (end of treatment)</time_frame>
    <description>Normalization for OABSS Total Score was defined as OABSS total score ≤ 2 or OABSS Question 3 score ≤ 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Overactive Bladder Questionnaire Short Form (OAB-q SF) Symptom Severity Score</measure>
    <time_frame>Baseline and week 12, 28 and 52</time_frame>
    <description>The OAB-q SF questionnaire was a questionnaire completed by participants composed of 2 sections: Symptom Severity and the Health-related Quality of Life (HRQL). The Symptom Severity section included 6 questions. For each participant, the symptom severity score was derived as a sum of scores for Questions 1 to 6. The total score ranges from 6 to 36 with higher symptom severity score indicating greater symptom bother. OAB-q SF data obtained at week 0 visit were used as baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in OAB-q SF Total HRQL Score</measure>
    <time_frame>Baseline and week 12, 28 and 52</time_frame>
    <description>The OAB-q SF questionnaire was a questionnaire completed by participants composed of 2 sections: Severity Symptom and the HRQL. The HRQL section included 13 questions. For each participant, the total HRQL score was derived as a sum of scores for Questions 7 to 19. The total score ranges from 13 to 78 with higher total HRQL score indicating greater HRQL. OAB-q SF data obtained at week 0 visit were used as baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Number of Micturitions Per 24 Hours</measure>
    <time_frame>Baseline and week 4, 8, 12, 16, 28, 40, 52</time_frame>
    <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. The mean number of micturitions per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable &quot;urinated&quot; was indicated, divided by the number of days on which episodes were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number for Participants Who Achieved Normalization of the Mean Number of Micturitions Per 24 Hours</measure>
    <time_frame>Week 52 (end of treatment)</time_frame>
    <description>Normalization for the mean number of micturitions per 24 hours was defined as &lt; 8 micturitions per 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Number of Urgency Episodes Per 24 Hours</measure>
    <time_frame>Baseline and week 4, 8, 12, 16, 28, 40, 52</time_frame>
    <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. An urgency episode was defined as a complaint of a sudden, compelling desire to pass urine, which is difficult to defer. The mean number of urgency episodes per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable &quot;urgency&quot; was indicated, divided by the number of days on which episodes were recorded. Only participants who had an urgency episode at baseline was included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number for Participants Who Achieved Normalization of the Mean Number of Urgency Episodes Per 24 Hours</measure>
    <time_frame>Week 52 (end of treatment)</time_frame>
    <description>Normalization for the mean number of urgency episodes per 24 hours was defined as no urgency episode per 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Number of Incontinence Episodes Per 24 Hours</measure>
    <time_frame>Baseline and week 4, 8, 12, 16, 28, 40, 52</time_frame>
    <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable &quot;urinary incontinence'&quot; was indicated, divided by the number of days on which episodes were recorded. Only participants who had an incontinence episode at baseline was included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number for Participants Who Achieved Normalization of the Mean Number of Incontinence Episodes Per 24 Hours</measure>
    <time_frame>Week 52 (end of treatment)</time_frame>
    <description>Normalization for the mean number of incontinence episodes per 24 hours was defined as no incontinence episode per 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Number of Urge Incontinence Episodes Per 24 Hours</measure>
    <time_frame>Baseline and week 4, 8, 12, 16, 28, 40, 52</time_frame>
    <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. An urge incontinence episode was defined as any episode when both urgency and incontinence occurred concurrently. The mean number of incontinence episodes per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable &quot;urgency&quot; and &quot;urinary incontinence'&quot; were indicated, divided by the number of days on which episodes were recorded. Only participants who had an urge incontinence episode at baseline was included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Volume Voided Per Micturition</measure>
    <time_frame>Baseline and week 4, 8, 12, 16, 28, 40, 52</time_frame>
    <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. The mean volume per micturition was calculated by taking the sum of the urinary volumes where the volume voided was &gt; 0 and where &quot;urinary incontinence&quot; was not indicated in the patient diary, divided by the number of micturitions where the volume voided was &gt; 0 and where &quot;urinary incontinence&quot; was not indicated. Only participants who had volume voided was &gt; 0 at baseline was included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Number of Nocturia Episodes Per Night</measure>
    <time_frame>Baseline and week 4, 8, 12, 16, 28, 40, 52</time_frame>
    <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. A nocturia episode was defined as waking at night 1 or more times to void. Night time was defined as the period between bedtime and the wake-up time the following day (micturitions at the same time as the wake-up time were excluded). The mean number of nocturia episodes per night was calculated by taking the sum of nocturia episodes in the patient diary where the variable &quot;urinated&quot; was indicated during the night time, divided by the number of nights. Only participants who had a nocturia episode at baseline was included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved Normalization of the Mean Number of Nocturia Episodes Per 24 Hours</measure>
    <time_frame>Week 52 (end of treatment)</time_frame>
    <description>Normalization for the mean number of nocturia episodes per 24 hours was defined as no nocturia episode per 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postvoid Residual (PVR) Volume</measure>
    <time_frame>Baseline and week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52</time_frame>
    <description>Measurement of PVR volume was made using either ultrasonography or urethral catheterization, provided that the same method was used for the same participant throughout the study.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">649</enrollment>
  <condition>Overactive Bladder (OAB)</condition>
  <arm_group>
    <arm_group_label>Mirabegron + Solifenacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirabegron + Propiverine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirabegron + Imidafenacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirabegron + Tolterodine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron tablet</intervention_name>
    <description>orally administered at a dose of 1 tablet once daily after breakfast</description>
    <arm_group_label>Mirabegron + Imidafenacin</arm_group_label>
    <arm_group_label>Mirabegron + Propiverine</arm_group_label>
    <arm_group_label>Mirabegron + Solifenacin</arm_group_label>
    <arm_group_label>Mirabegron + Tolterodine</arm_group_label>
    <other_name>YM178</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin tablet</intervention_name>
    <description>orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 2 tablets)</description>
    <arm_group_label>Mirabegron + Solifenacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propiverine tablet</intervention_name>
    <description>orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 1 tablet twice daily after breakfast and after dinner)</description>
    <arm_group_label>Mirabegron + Propiverine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imidafenacin tablet</intervention_name>
    <description>orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (could be increased to 2 tablets twice daily after breakfast and after dinner)</description>
    <arm_group_label>Mirabegron + Imidafenacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine capsule</intervention_name>
    <description>orally administered at a dose of 1 capsule once daily after breakfast (could not be increased)</description>
    <arm_group_label>Mirabegron + Tolterodine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female: OAB outpatient who had been postmenopausal for at least 1 year

          -  Male: OAB outpatient who had no wish to have children in the future

          -  Patient had been under treatment with mirabegron at a stable dose of 50 mg once daily
             for at least 6 weeks before the start of the screening period

          -  Patient capable of walking to the bathroom without assistance

          -  Patient had a total Overactive Bladder Symptom Score (OABSS) of ≥3 points and a
             Question 3 score of ≥2 points

        Exclusion Criteria:

          -  Patient had an established diagnosis of stress urinary incontinence (patient had no
             symptom other than stress urinary incontinence)

          -  Patient had urinary tract infection (cystitis, prostatitis, etc.), urinary calculus
             (ureteric calculus, urethral calculus, bladder calculus, etc.), interstitial cystitis,
             or a history of recurrent urinary tract infection (at least 3 episodes within 24 weeks
             before the start of the screening period)

          -  Patient had a residual urine volume of ≥100 mL at week -2 visit or patient with benign
             prostatic hyperplasia or lower urinary tract obstruction

          -  Patient had uncontrolled hypertension (sitting systolic blood pressure ≥180 mmHg or
             diastolic blood pressure ≥110 mmHg at week -2 visit)

          -  Patient had a pulse rate of ≥110 bpm or &lt;50 bpm at week -2 visit

          -  Patient had a contraindication to antimuscarinics (urinary retention; obstruction in
             thepylorus, duodenum, or intestine; paralytic ileus; gastric/intestinal atony;
             myasthenia gravis; and decreased gastrointestinal motility/tone, etc.)

          -  Patient had glaucoma, ulcerative colitis, hyperthyroidism, dementia, cognitive
             dysfunction, parkinsonism symptoms, or clinically significant cerebrovascular disorder

          -  Patient had serious heart disease (myocardial infarction, cardiac failure,
             uncontrolled angina pectoris, serious arrhythmia, use of pacemaker, etc.), liver
             disease, kidney disease, immunological disease, lung disease, etc. or patient had a
             history of malignant tumor (except for malignant tumor that had not been treated for
             at least 5 years before the start of the screening period with no risk of recurrence)

          -  Patient had drug hypersensitivity to β-agonists or anticholinergics

          -  Patient was under treatment with flecainide acetate or propafenone hydrochloride

          -  Patient had long QT syndrome, patient was vulnerable to arrhythmia such as bradycardia
             or acute myocardial ischemia, patient had hypokalemia, and patient had ischemic heart
             disease such as angina pectoris

          -  Patient had used any prohibited concomitant medication within 4 weeks before the start
             of the screening period

          -  Patient was under catheterization or intermittent self-catheterization or patient had
             pelvic organ prolapse that affected the urinary tract function

          -  Patient had received radiotherapy that affected the urinary tract function

          -  Patient had received surgical therapy that may have affected the urinary tract
             function within 24 weeks before the start of the screening period

          -  Patient had received nonpharmacological therapy for OAB such as electric stimulation
             therapy (interferential low frequency therapy, magnetic stimulation therapy, etc.),
             biofeedback therapy, bladder training, or pelvic floor muscle exercise within 2 weeks
             before the start of the screening period

          -  Patient had or had a history of mood disorder, neurotic disorder, and schizophrenia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tohoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/study.aspx?ID=224</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2014</study_first_posted>
  <results_first_submitted>May 7, 2018</results_first_submitted>
  <results_first_submitted_qc>December 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 24, 2018</results_first_posted>
  <disposition_first_submitted>August 31, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>August 31, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 6, 2017</disposition_first_posted>
  <last_update_submitted>January 9, 2019</last_update_submitted>
  <last_update_submitted_qc>January 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anticholinergic</keyword>
  <keyword>Overactive Bladder (OAB)</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>YM178</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
    <mesh_term>Tolterodine Tartrate</mesh_term>
    <mesh_term>Propiverine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the trial, in addition to study-related supporting documentation, is planned for trials conducted with approved product indications and formulations, as well as compounds terminated during development. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with overactive bladder (OAB) were enrolled in 60 sites in Japan.</recruitment_details>
      <pre_assignment_details>Prior to randomization, participants received 50 mg mirabegron orally once daily after breakfast for 2 weeks during a screening period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mirabegron + Solifenacin</title>
          <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
        </group>
        <group group_id="P2">
          <title>Mirabegron + Propiverine</title>
          <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
        </group>
        <group group_id="P3">
          <title>Mirabegron + Imidafenacin</title>
          <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
        </group>
        <group group_id="P4">
          <title>Mirabegron + Tolterodine</title>
          <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
                <participants group_id="P2" count="161"/>
                <participants group_id="P3" count="161"/>
                <participants group_id="P4" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="128"/>
                <participants group_id="P3" count="126"/>
                <participants group_id="P4" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Electrocardiogram adviser's judgment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set (SAF). The SAF consisted of participants who received at least 1 dose of the study drug for the treatment period.</population>
      <group_list>
        <group group_id="B1">
          <title>Mirabegron + Solifenacin</title>
          <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
        </group>
        <group group_id="B2">
          <title>Mirabegron + Propiverine</title>
          <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
        </group>
        <group group_id="B3">
          <title>Mirabegron + Imidafenacin</title>
          <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
        </group>
        <group group_id="B4">
          <title>Mirabegron + Tolterodine</title>
          <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="166"/>
            <count group_id="B2" value="161"/>
            <count group_id="B3" value="161"/>
            <count group_id="B4" value="159"/>
            <count group_id="B5" value="647"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                    <count group_id="B2" value="161"/>
                    <count group_id="B3" value="161"/>
                    <count group_id="B4" value="159"/>
                    <count group_id="B5" value="647"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="9.4"/>
                    <measurement group_id="B2" value="64.0" spread="9.3"/>
                    <measurement group_id="B3" value="65.7" spread="8.7"/>
                    <measurement group_id="B4" value="65.7" spread="10.0"/>
                    <measurement group_id="B5" value="65.0" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                    <count group_id="B2" value="161"/>
                    <count group_id="B3" value="161"/>
                    <count group_id="B4" value="159"/>
                    <count group_id="B5" value="647"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="134"/>
                    <measurement group_id="B5" value="570"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Overactive Bladder Symptom Score (OABSS)</title>
          <description>The OABSS questionnaire was a questionnaire completed by participants with 4 questions regarding their OAB symptoms. For each participant, the OABSS total score was calculated from the sum total of the score of each question. The total score ranges from 0 to 15 with higher score indicating more symptoms. The OABSS data obtained at week 0 were used as baseline.</description>
          <population>Full Analysis Set (FAS). The FAS consisted of participants who received at least 1 dose of the study drugs for the treatment period and who provided evaluable efficacy data for at least 1 variable before and after the start of the treatment period. Participants with available data are included in the analysis.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                    <count group_id="B2" value="161"/>
                    <count group_id="B3" value="161"/>
                    <count group_id="B4" value="159"/>
                    <count group_id="B5" value="647"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.4" spread="2.6"/>
                    <measurement group_id="B2" value="7.7" spread="2.5"/>
                    <measurement group_id="B3" value="7.8" spread="2.3"/>
                    <measurement group_id="B4" value="7.7" spread="2.3"/>
                    <measurement group_id="B5" value="7.6" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Overactive Bladder questionnaire Short Form (OAB-q SF) Score: Symptom Severity</title>
          <description>The OAB-q SF questionnaire was a questionnaire completed by participants composed of 2 sections: Severity Symptom and the Health-related Quality of Life (HRQL). The Severity Symptom section included 6 questions. For each participant, the symptom severity score was derived as a sum of scores for Questions 1 to 6. The total score ranges from 6 to 36 with higher symptom severity score indicating greater symptom bother. OAB-q SF data obtained at week 0 visit were used as baseline.</description>
          <population>FAS participants with available data are included in the analysis.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                    <count group_id="B2" value="161"/>
                    <count group_id="B3" value="161"/>
                    <count group_id="B4" value="159"/>
                    <count group_id="B5" value="647"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.81" spread="20.78"/>
                    <measurement group_id="B2" value="32.36" spread="21.23"/>
                    <measurement group_id="B3" value="32.92" spread="19.45"/>
                    <measurement group_id="B4" value="34.23" spread="22.60"/>
                    <measurement group_id="B5" value="33.08" spread="21.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>OAB-q SF Score: Total Health-Related Quality of Life (HRQOL)</title>
          <description>The OAB-q SF questionnaire was a questionnaire completed by participants composed of 2 sections: Severity Symptom and the HRQL. The HRQL section included 13 questions. For each participant, the total HRQL score was derived as a sum of scores for Questions 7 to 19. The total score ranges from 13 to 78 with higher total HRQL score indicating greater HRQL. OAB-q SF data obtained at week 0 visit were used as baseline.</description>
          <population>FAS participants with available data are included in the analysis.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                    <count group_id="B2" value="161"/>
                    <count group_id="B3" value="161"/>
                    <count group_id="B4" value="159"/>
                    <count group_id="B5" value="647"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.16" spread="17.65"/>
                    <measurement group_id="B2" value="77.36" spread="16.11"/>
                    <measurement group_id="B3" value="74.85" spread="18.50"/>
                    <measurement group_id="B4" value="75.37" spread="19.33"/>
                    <measurement group_id="B5" value="75.68" spread="17.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Number of Micturitions per 24 Hours</title>
          <description>The mean number of micturitions per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable &quot;urinated&quot; was indicated, divided by the number of days on which episodes were recorded.</description>
          <population>FAS participants with available data are included in the analysis.</population>
          <units>micturitions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                    <count group_id="B2" value="161"/>
                    <count group_id="B3" value="161"/>
                    <count group_id="B4" value="159"/>
                    <count group_id="B5" value="647"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.06" spread="2.59"/>
                    <measurement group_id="B2" value="10.37" spread="2.65"/>
                    <measurement group_id="B3" value="10.13" spread="2.92"/>
                    <measurement group_id="B4" value="10.20" spread="2.62"/>
                    <measurement group_id="B5" value="10.19" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Number of Urgency Episodes per 24 Hours</title>
          <description>An urgency episode was defined as a complaint of a sudden, compelling desire to pass urine, which is difficult to defer. The mean number of urgency episodes per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable &quot;urgency&quot; was indicated, divided by the number of days on which episodes were recorded. Only participants who had an urgency episode at baseline was included in the analysis.</description>
          <population>FAS participants with available data are included in the analysis.</population>
          <units>urgency episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="153"/>
                    <count group_id="B2" value="148"/>
                    <count group_id="B3" value="150"/>
                    <count group_id="B4" value="148"/>
                    <count group_id="B5" value="599"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.26" spread="2.46"/>
                    <measurement group_id="B2" value="3.12" spread="2.67"/>
                    <measurement group_id="B3" value="3.27" spread="2.20"/>
                    <measurement group_id="B4" value="3.15" spread="2.54"/>
                    <measurement group_id="B5" value="3.20" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Number of Incontinence Episodes per 24 Hours</title>
          <description>An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable &quot;urinary incontinence’&quot; was indicated, divided by the number of days on which episodes were recorded. Only participants who had an incontinence episode at baseline was included in the analysis.</description>
          <population>FAS participants with available data are included in the analysis.</population>
          <units>incontinence episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="91"/>
                    <count group_id="B2" value="95"/>
                    <count group_id="B3" value="103"/>
                    <count group_id="B4" value="96"/>
                    <count group_id="B5" value="385"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.62" spread="1.62"/>
                    <measurement group_id="B2" value="1.59" spread="1.83"/>
                    <measurement group_id="B3" value="1.47" spread="1.35"/>
                    <measurement group_id="B4" value="1.55" spread="1.76"/>
                    <measurement group_id="B5" value="1.56" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Number of Urge Incontinence Episodes per 24 Hours</title>
          <description>An urge incontinence episode was defined as any episode when both urgency and incontinence occurred concurrently. The mean number of incontinence episodes per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable &quot;urgency&quot; and &quot;urinary incontinence’&quot; were indicated, divided by the number of days on which episodes were recorded. Only participants who had an urge incontinence episode at baseline was included in the analysis.</description>
          <population>FAS participants with available data are included in the analysis.</population>
          <units>urge incontinence episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="82"/>
                    <count group_id="B3" value="86"/>
                    <count group_id="B4" value="85"/>
                    <count group_id="B5" value="333"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.55" spread="1.47"/>
                    <measurement group_id="B2" value="1.39" spread="1.45"/>
                    <measurement group_id="B3" value="1.30" spread="1.16"/>
                    <measurement group_id="B4" value="1.31" spread="1.62"/>
                    <measurement group_id="B5" value="1.38" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Volume Voided per Micturition</title>
          <description>The mean volume per micturition was calculated by taking the sum of the urinary volumes where the volume voided was &gt; 0 and where &quot;urinary incontinence&quot; was not indicated in the patient diary, divided by the number of micturitions where the volume voided was &gt; 0 and where &quot;urinary incontinence&quot; was not indicated. Only participants who had volume voided was &gt; 0 at baseline was included in the analysis.</description>
          <population>FAS participants with available data are included in the analysis.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                    <count group_id="B2" value="161"/>
                    <count group_id="B3" value="161"/>
                    <count group_id="B4" value="159"/>
                    <count group_id="B5" value="647"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.600" spread="50.404"/>
                    <measurement group_id="B2" value="170.064" spread="63.781"/>
                    <measurement group_id="B3" value="169.309" spread="50.324"/>
                    <measurement group_id="B4" value="167.542" spread="54.320"/>
                    <measurement group_id="B5" value="168.368" spread="54.839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Number of Nocturia Episodes per Night</title>
          <description>A nocturia episode was defined as waking at night 1 or more times to void. Night time was defined as the period between bedtime and the wake-up time the following day (micturitions at the same time as the wake-up time were excluded). The mean number of nocturia episodes per night was calculated by taking the sum of nocturia episodes in the patient diary where the variable &quot;urinated&quot; was indicated during the night time, divided by the number of nights. Only participants who had a nocturia episode at baseline was included in the analysis.</description>
          <population>FAS participants with available data are included in the analysis.</population>
          <units>nocturia episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="142"/>
                    <count group_id="B2" value="133"/>
                    <count group_id="B3" value="141"/>
                    <count group_id="B4" value="132"/>
                    <count group_id="B5" value="548"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.50" spread="0.96"/>
                    <measurement group_id="B2" value="1.68" spread="1.08"/>
                    <measurement group_id="B3" value="1.61" spread="1.29"/>
                    <measurement group_id="B4" value="1.67" spread="1.04"/>
                    <measurement group_id="B5" value="1.61" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Postvoid Residual (PVR) Volume</title>
          <description>Measurement of PVR volume was made using either ultrasonography or urethral catheterization, provided that the same method was used for the same participant throughout the study.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                    <count group_id="B2" value="161"/>
                    <count group_id="B3" value="161"/>
                    <count group_id="B4" value="159"/>
                    <count group_id="B5" value="647"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.02" spread="15.43"/>
                    <measurement group_id="B2" value="10.43" spread="17.07"/>
                    <measurement group_id="B3" value="9.74" spread="14.35"/>
                    <measurement group_id="B4" value="9.10" spread="14.41"/>
                    <measurement group_id="B5" value="10.08" spread="15.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>TEAEs were defined as AEs observed after the first administration of the study drugs for the treatment period. The investigator assessed the severity of AEs, including abnormal clinical laboratory values, electrocardiogram (ECG), vital signs, as follows: Mild: No disruption of normal daily activities; Moderate: Affected normal daily activities; Severe: Inability to perform daily activities. A drug-related TEAE was a TEAE with at least a possible relationship to the study drug as assessed by the investigator.</description>
        <time_frame>From first dose of study drug up to week 52</time_frame>
        <population>SAF</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron + Solifenacin</title>
            <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron + Propiverine</title>
            <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron + Imidafenacin</title>
            <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O4">
            <title>Mirabegron + Tolterodine</title>
            <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>TEAEs were defined as AEs observed after the first administration of the study drugs for the treatment period. The investigator assessed the severity of AEs, including abnormal clinical laboratory values, electrocardiogram (ECG), vital signs, as follows: Mild: No disruption of normal daily activities; Moderate: Affected normal daily activities; Severe: Inability to perform daily activities. A drug-related TEAE was a TEAE with at least a possible relationship to the study drug as assessed by the investigator.</description>
          <population>SAF</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="161"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="135"/>
                    <measurement group_id="O3" value="133"/>
                    <measurement group_id="O4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="116"/>
                    <measurement group_id="O4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to withdrawal of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs leading to withdrawal of treat.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Overactive Bladder Symptom Score (OABSS) Total Score</title>
        <description>The OABSS questionnaire was a questionnaire completed by participants with 4 questions regarding their OAB symptoms. For each participant, the OABSS total score was calculated from the sum total of the score of each question. The total score ranges from 0 to 15 with higher score indicating more symptoms. The OABSS data obtained at week 0 were used as baseline.</description>
        <time_frame>Baseline and week 4, 8, 12, 16, 28 and 52</time_frame>
        <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron + Solifenacin</title>
            <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron + Propiverine</title>
            <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron + Imidafenacin</title>
            <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O4">
            <title>Mirabegron + Tolterodine</title>
            <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Overactive Bladder Symptom Score (OABSS) Total Score</title>
          <description>The OABSS questionnaire was a questionnaire completed by participants with 4 questions regarding their OAB symptoms. For each participant, the OABSS total score was calculated from the sum total of the score of each question. The total score ranges from 0 to 15 with higher score indicating more symptoms. The OABSS data obtained at week 0 were used as baseline.</description>
          <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="161"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="158"/>
                    <count group_id="O4" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="2.5"/>
                    <measurement group_id="O2" value="-3.1" spread="2.5"/>
                    <measurement group_id="O3" value="-2.4" spread="2.3"/>
                    <measurement group_id="O4" value="-3.0" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="148"/>
                    <count group_id="O3" value="155"/>
                    <count group_id="O4" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="2.5"/>
                    <measurement group_id="O2" value="-3.7" spread="2.5"/>
                    <measurement group_id="O3" value="-3.1" spread="2.3"/>
                    <measurement group_id="O4" value="-3.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="146"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="2.6"/>
                    <measurement group_id="O2" value="-4.2" spread="2.8"/>
                    <measurement group_id="O3" value="-3.4" spread="2.2"/>
                    <measurement group_id="O4" value="-4.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="144"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="2.7"/>
                    <measurement group_id="O2" value="-4.4" spread="2.7"/>
                    <measurement group_id="O3" value="-3.8" spread="2.3"/>
                    <measurement group_id="O4" value="-4.4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="140"/>
                    <count group_id="O4" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="2.6"/>
                    <measurement group_id="O2" value="-4.4" spread="2.9"/>
                    <measurement group_id="O3" value="-3.9" spread="2.8"/>
                    <measurement group_id="O4" value="-4.3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="2.7"/>
                    <measurement group_id="O2" value="-4.1" spread="2.5"/>
                    <measurement group_id="O3" value="-4.1" spread="2.6"/>
                    <measurement group_id="O4" value="-4.3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="161"/>
                    <count group_id="O4" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="2.7"/>
                    <measurement group_id="O2" value="-4.1" spread="2.6"/>
                    <measurement group_id="O3" value="-3.9" spread="2.6"/>
                    <measurement group_id="O4" value="-4.2" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved Normalization for OABSS Total Score</title>
        <description>Normalization for OABSS Total Score was defined as OABSS total score ≤ 2 or OABSS Question 3 score ≤ 1.</description>
        <time_frame>Week 52 (end of treatment)</time_frame>
        <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron + Solifenacin</title>
            <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron + Propiverine</title>
            <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron + Imidafenacin</title>
            <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O4">
            <title>Mirabegron + Tolterodine</title>
            <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved Normalization for OABSS Total Score</title>
          <description>Normalization for OABSS Total Score was defined as OABSS total score ≤ 2 or OABSS Question 3 score ≤ 1.</description>
          <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="161"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="91"/>
                    <measurement group_id="O4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Overactive Bladder Questionnaire Short Form (OAB-q SF) Symptom Severity Score</title>
        <description>The OAB-q SF questionnaire was a questionnaire completed by participants composed of 2 sections: Symptom Severity and the Health-related Quality of Life (HRQL). The Symptom Severity section included 6 questions. For each participant, the symptom severity score was derived as a sum of scores for Questions 1 to 6. The total score ranges from 6 to 36 with higher symptom severity score indicating greater symptom bother. OAB-q SF data obtained at week 0 visit were used as baseline.</description>
        <time_frame>Baseline and week 12, 28 and 52</time_frame>
        <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron + Solifenacin</title>
            <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron + Propiverine</title>
            <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron + Imidafenacin</title>
            <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O4">
            <title>Mirabegron + Tolterodine</title>
            <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Overactive Bladder Questionnaire Short Form (OAB-q SF) Symptom Severity Score</title>
          <description>The OAB-q SF questionnaire was a questionnaire completed by participants composed of 2 sections: Symptom Severity and the Health-related Quality of Life (HRQL). The Symptom Severity section included 6 questions. For each participant, the symptom severity score was derived as a sum of scores for Questions 1 to 6. The total score ranges from 6 to 36 with higher symptom severity score indicating greater symptom bother. OAB-q SF data obtained at week 0 visit were used as baseline.</description>
          <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="161"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="146"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.59" spread="15.89"/>
                    <measurement group_id="O2" value="-20.2" spread="19.40"/>
                    <measurement group_id="O3" value="-17.15" spread="17.37"/>
                    <measurement group_id="O4" value="-21.22" spread="20.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="140"/>
                    <count group_id="O4" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.38" spread="18.15"/>
                    <measurement group_id="O2" value="-21.40" spread="19.18"/>
                    <measurement group_id="O3" value="-20.40" spread="19.23"/>
                    <measurement group_id="O4" value="-21.95" spread="20.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.55" spread="18.29"/>
                    <measurement group_id="O2" value="-20.68" spread="19.33"/>
                    <measurement group_id="O3" value="-20.51" spread="18.28"/>
                    <measurement group_id="O4" value="-22.49" spread="21.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="160"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.92" spread="18.42"/>
                    <measurement group_id="O2" value="-18.99" spread="19.14"/>
                    <measurement group_id="O3" value="-18.89" spread="18.11"/>
                    <measurement group_id="O4" value="-21.28" spread="20.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in OAB-q SF Total HRQL Score</title>
        <description>The OAB-q SF questionnaire was a questionnaire completed by participants composed of 2 sections: Severity Symptom and the HRQL. The HRQL section included 13 questions. For each participant, the total HRQL score was derived as a sum of scores for Questions 7 to 19. The total score ranges from 13 to 78 with higher total HRQL score indicating greater HRQL. OAB-q SF data obtained at week 0 visit were used as baseline.</description>
        <time_frame>Baseline and week 12, 28 and 52</time_frame>
        <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron + Solifenacin</title>
            <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron + Propiverine</title>
            <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron + Imidafenacin</title>
            <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O4">
            <title>Mirabegron + Tolterodine</title>
            <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in OAB-q SF Total HRQL Score</title>
          <description>The OAB-q SF questionnaire was a questionnaire completed by participants composed of 2 sections: Severity Symptom and the HRQL. The HRQL section included 13 questions. For each participant, the total HRQL score was derived as a sum of scores for Questions 7 to 19. The total score ranges from 13 to 78 with higher total HRQL score indicating greater HRQL. OAB-q SF data obtained at week 0 visit were used as baseline.</description>
          <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="161"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="146"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.07" spread="13.37"/>
                    <measurement group_id="O2" value="11.35" spread="13.15"/>
                    <measurement group_id="O3" value="11.06" spread="15.72"/>
                    <measurement group_id="O4" value="12.05" spread="16.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="140"/>
                    <count group_id="O4" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.15" spread="14.63"/>
                    <measurement group_id="O2" value="13.05" spread="14.00"/>
                    <measurement group_id="O3" value="14.88" spread="17.16"/>
                    <measurement group_id="O4" value="12.94" spread="15.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.99" spread="14.63"/>
                    <measurement group_id="O2" value="13.89" spread="14.04"/>
                    <measurement group_id="O3" value="14.67" spread="16.88"/>
                    <measurement group_id="O4" value="15.06" spread="16.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="160"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.38" spread="14.98"/>
                    <measurement group_id="O2" value="12.46" spread="13.89"/>
                    <measurement group_id="O3" value="13.99" spread="16.72"/>
                    <measurement group_id="O4" value="14.36" spread="17.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Number of Micturitions Per 24 Hours</title>
        <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. The mean number of micturitions per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable &quot;urinated&quot; was indicated, divided by the number of days on which episodes were recorded.</description>
        <time_frame>Baseline and week 4, 8, 12, 16, 28, 40, 52</time_frame>
        <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron + Solifenacin</title>
            <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron + Propiverine</title>
            <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron + Imidafenacin</title>
            <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O4">
            <title>Mirabegron + Tolterodine</title>
            <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Number of Micturitions Per 24 Hours</title>
          <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. The mean number of micturitions per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable &quot;urinated&quot; was indicated, divided by the number of days on which episodes were recorded.</description>
          <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
          <units>micturitions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="161"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="1.52"/>
                    <measurement group_id="O2" value="-1.44" spread="1.70"/>
                    <measurement group_id="O3" value="-1.23" spread="1.80"/>
                    <measurement group_id="O4" value="-1.51" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="154"/>
                    <count group_id="O2" value="148"/>
                    <count group_id="O3" value="153"/>
                    <count group_id="O4" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.85" spread="1.69"/>
                    <measurement group_id="O2" value="-1.89" spread="1.87"/>
                    <measurement group_id="O3" value="-1.62" spread="1.95"/>
                    <measurement group_id="O4" value="-1.72" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="146"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" spread="1.74"/>
                    <measurement group_id="O2" value="-1.90" spread="1.96"/>
                    <measurement group_id="O3" value="-1.74" spread="1.90"/>
                    <measurement group_id="O4" value="-2.18" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="144"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.33" spread="1.74"/>
                    <measurement group_id="O2" value="-2.21" spread="2.03"/>
                    <measurement group_id="O3" value="-1.86" spread="2.00"/>
                    <measurement group_id="O4" value="-2.20" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="134"/>
                    <count group_id="O3" value="139"/>
                    <count group_id="O4" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="2.05"/>
                    <measurement group_id="O2" value="-2.10" spread="2.16"/>
                    <measurement group_id="O3" value="-1.97" spread="2.39"/>
                    <measurement group_id="O4" value="2.33" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.12" spread="2.01"/>
                    <measurement group_id="O2" value="-1.97" spread="2.17"/>
                    <measurement group_id="O3" value="-1.80" spread="2.14"/>
                    <measurement group_id="O4" value="-1.92" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="2.01"/>
                    <measurement group_id="O2" value="-2.08" spread="2.11"/>
                    <measurement group_id="O3" value="-1.82" spread="2.16"/>
                    <measurement group_id="O4" value="-1.80" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="159"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" spread="1.96"/>
                    <measurement group_id="O2" value="-1.89" spread="2.08"/>
                    <measurement group_id="O3" value="-1.75" spread="2.09"/>
                    <measurement group_id="O4" value="-1.91" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number for Participants Who Achieved Normalization of the Mean Number of Micturitions Per 24 Hours</title>
        <description>Normalization for the mean number of micturitions per 24 hours was defined as &lt; 8 micturitions per 24 hours.</description>
        <time_frame>Week 52 (end of treatment)</time_frame>
        <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron + Solifenacin</title>
            <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron + Propiverine</title>
            <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron + Imidafenacin</title>
            <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O4">
            <title>Mirabegron + Tolterodine</title>
            <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number for Participants Who Achieved Normalization of the Mean Number of Micturitions Per 24 Hours</title>
          <description>Normalization for the mean number of micturitions per 24 hours was defined as &lt; 8 micturitions per 24 hours.</description>
          <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Number of Urgency Episodes Per 24 Hours</title>
        <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. An urgency episode was defined as a complaint of a sudden, compelling desire to pass urine, which is difficult to defer. The mean number of urgency episodes per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable &quot;urgency&quot; was indicated, divided by the number of days on which episodes were recorded. Only participants who had an urgency episode at baseline was included in the analysis.</description>
        <time_frame>Baseline and week 4, 8, 12, 16, 28, 40, 52</time_frame>
        <population>FAS participants with available data at each time point are included in the analysis.A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron + Solifenacin</title>
            <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron + Propiverine</title>
            <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron + Imidafenacin</title>
            <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O4">
            <title>Mirabegron + Tolterodine</title>
            <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Number of Urgency Episodes Per 24 Hours</title>
          <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. An urgency episode was defined as a complaint of a sudden, compelling desire to pass urine, which is difficult to defer. The mean number of urgency episodes per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable &quot;urgency&quot; was indicated, divided by the number of days on which episodes were recorded. Only participants who had an urgency episode at baseline was included in the analysis.</description>
          <population>FAS participants with available data at each time point are included in the analysis.A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
          <units>urgency episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="143"/>
                    <count group_id="O3" value="149"/>
                    <count group_id="O4" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.53" spread="1.99"/>
                    <measurement group_id="O2" value="-1.63" spread="2.20"/>
                    <measurement group_id="O3" value="-1.23" spread="1.62"/>
                    <measurement group_id="O4" value="-1.49" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="139"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.78" spread="2.13"/>
                    <measurement group_id="O2" value="-1.90" spread="2.20"/>
                    <measurement group_id="O3" value="-1.50" spread="1.65"/>
                    <measurement group_id="O4" value="-1.89" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="2.20"/>
                    <measurement group_id="O2" value="-2.18" spread="2.39"/>
                    <measurement group_id="O3" value="-1.88" spread="1.78"/>
                    <measurement group_id="O4" value="-2.10" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="136"/>
                    <count group_id="O4" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.30" spread="2.22"/>
                    <measurement group_id="O2" value="-2.36" spread="2.56"/>
                    <measurement group_id="O3" value="-2.01" spread="1.89"/>
                    <measurement group_id="O4" value="-2.26" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="2.25"/>
                    <measurement group_id="O2" value="-2.26" spread="2.76"/>
                    <measurement group_id="O3" value="-2.18" spread="2.10"/>
                    <measurement group_id="O4" value="-2.28" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.14" spread="2.33"/>
                    <measurement group_id="O2" value="-2.27" spread="2.64"/>
                    <measurement group_id="O3" value="-2.14" spread="2.17"/>
                    <measurement group_id="O4" value="-2.19" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="117"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" spread="2.69"/>
                    <measurement group_id="O2" value="-2.33" spread="2.54"/>
                    <measurement group_id="O3" value="-2.15" spread="2.28"/>
                    <measurement group_id="O4" value="-2.26" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="143"/>
                    <count group_id="O3" value="149"/>
                    <count group_id="O4" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" spread="2.55"/>
                    <measurement group_id="O2" value="-2.24" spread="2.41"/>
                    <measurement group_id="O3" value="-2.04" spread="2.19"/>
                    <measurement group_id="O4" value="-2.07" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number for Participants Who Achieved Normalization of the Mean Number of Urgency Episodes Per 24 Hours</title>
        <description>Normalization for the mean number of urgency episodes per 24 hours was defined as no urgency episode per 24 hours.</description>
        <time_frame>Week 52 (end of treatment)</time_frame>
        <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron + Solifenacin</title>
            <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron + Propiverine</title>
            <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron + Imidafenacin</title>
            <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O4">
            <title>Mirabegron + Tolterodine</title>
            <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number for Participants Who Achieved Normalization of the Mean Number of Urgency Episodes Per 24 Hours</title>
          <description>Normalization for the mean number of urgency episodes per 24 hours was defined as no urgency episode per 24 hours.</description>
          <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Number of Incontinence Episodes Per 24 Hours</title>
        <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable &quot;urinary incontinence'&quot; was indicated, divided by the number of days on which episodes were recorded. Only participants who had an incontinence episode at baseline was included in the analysis.</description>
        <time_frame>Baseline and week 4, 8, 12, 16, 28, 40, 52</time_frame>
        <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron + Solifenacin</title>
            <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron + Propiverine</title>
            <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron + Imidafenacin</title>
            <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O4">
            <title>Mirabegron + Tolterodine</title>
            <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Number of Incontinence Episodes Per 24 Hours</title>
          <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable &quot;urinary incontinence'&quot; was indicated, divided by the number of days on which episodes were recorded. Only participants who had an incontinence episode at baseline was included in the analysis.</description>
          <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis</population>
          <units>incontinence episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="101"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.13" spread="1.40"/>
                    <measurement group_id="O2" value="-1.06" spread="1.50"/>
                    <measurement group_id="O3" value="-0.81" spread="0.95"/>
                    <measurement group_id="O4" value="-1.09" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="1.44"/>
                    <measurement group_id="O2" value="-1.21" spread="1.50"/>
                    <measurement group_id="O3" value="-0.74" spread="1.13"/>
                    <measurement group_id="O4" value="-1.21" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="1.44"/>
                    <measurement group_id="O2" value="-1.34" spread="1.66"/>
                    <measurement group_id="O3" value="-0.86" spread="1.06"/>
                    <measurement group_id="O4" value="-1.23" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" spread="1.42"/>
                    <measurement group_id="O2" value="-1.32" spread="1.74"/>
                    <measurement group_id="O3" value="-0.97" spread="1.02"/>
                    <measurement group_id="O4" value="-1.33" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="1.53"/>
                    <measurement group_id="O2" value="-1.28" spread="1.82"/>
                    <measurement group_id="O3" value="-0.99" spread="1.21"/>
                    <measurement group_id="O4" value="-1.28" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" spread="1.53"/>
                    <measurement group_id="O2" value="-1.28" spread="1.56"/>
                    <measurement group_id="O3" value="-0.96" spread="0.99"/>
                    <measurement group_id="O4" value="-1.07" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="1.49"/>
                    <measurement group_id="O2" value="-1.29" spread="1.71"/>
                    <measurement group_id="O3" value="-1.02" spread="1.08"/>
                    <measurement group_id="O4" value="-1.18" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="101"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="1.48"/>
                    <measurement group_id="O2" value="-1.18" spread="1.59"/>
                    <measurement group_id="O3" value="-1.03" spread="1.08"/>
                    <measurement group_id="O4" value="-1.15" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number for Participants Who Achieved Normalization of the Mean Number of Incontinence Episodes Per 24 Hours</title>
        <description>Normalization for the mean number of incontinence episodes per 24 hours was defined as no incontinence episode per 24 hours.</description>
        <time_frame>Week 52 (end of treatment)</time_frame>
        <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron + Solifenacin</title>
            <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron + Propiverine</title>
            <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron + Imidafenacin</title>
            <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O4">
            <title>Mirabegron + Tolterodine</title>
            <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number for Participants Who Achieved Normalization of the Mean Number of Incontinence Episodes Per 24 Hours</title>
          <description>Normalization for the mean number of incontinence episodes per 24 hours was defined as no incontinence episode per 24 hours.</description>
          <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Number of Urge Incontinence Episodes Per 24 Hours</title>
        <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. An urge incontinence episode was defined as any episode when both urgency and incontinence occurred concurrently. The mean number of incontinence episodes per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable &quot;urgency&quot; and &quot;urinary incontinence'&quot; were indicated, divided by the number of days on which episodes were recorded. Only participants who had an urge incontinence episode at baseline was included in the analysis.</description>
        <time_frame>Baseline and week 4, 8, 12, 16, 28, 40, 52</time_frame>
        <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron + Solifenacin</title>
            <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron + Propiverine</title>
            <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron + Imidafenacin</title>
            <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O4">
            <title>Mirabegron + Tolterodine</title>
            <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Number of Urge Incontinence Episodes Per 24 Hours</title>
          <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. An urge incontinence episode was defined as any episode when both urgency and incontinence occurred concurrently. The mean number of incontinence episodes per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable &quot;urgency&quot; and &quot;urinary incontinence'&quot; were indicated, divided by the number of days on which episodes were recorded. Only participants who had an urge incontinence episode at baseline was included in the analysis.</description>
          <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
          <units>urge incontinence episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.13" spread="1.24"/>
                    <measurement group_id="O2" value="-1.00" spread="1.32"/>
                    <measurement group_id="O3" value="-0.72" spread="0.64"/>
                    <measurement group_id="O4" value="-0.96" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="1.31"/>
                    <measurement group_id="O2" value="-1.14" spread="1.23"/>
                    <measurement group_id="O3" value="-0.71" spread="0.96"/>
                    <measurement group_id="O4" value="-1.05" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="1.27"/>
                    <measurement group_id="O2" value="-1.25" spread="1.39"/>
                    <measurement group_id="O3" value="-0.79" spread="0.88"/>
                    <measurement group_id="O4" value="-1.13" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="1.24"/>
                    <measurement group_id="O2" value="-1.22" spread="1.47"/>
                    <measurement group_id="O3" value="-0.87" spread="0.86"/>
                    <measurement group_id="O4" value="-1.22" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="1.34"/>
                    <measurement group_id="O2" value="-1.10" spread="1.49"/>
                    <measurement group_id="O3" value="-0.85" spread="1.15"/>
                    <measurement group_id="O4" value="-1.18" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="1.36"/>
                    <measurement group_id="O2" value="-1.14" spread="1.28"/>
                    <measurement group_id="O3" value="-0.91" spread="0.96"/>
                    <measurement group_id="O4" value="-1.07" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" spread="1.32"/>
                    <measurement group_id="O2" value="-1.14" spread="1.37"/>
                    <measurement group_id="O3" value="-0.93" spread="0.97"/>
                    <measurement group_id="O4" value="-1.15" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="1.32"/>
                    <measurement group_id="O2" value="-1.12" spread="1.33"/>
                    <measurement group_id="O3" value="-0.91" spread="0.93"/>
                    <measurement group_id="O4" value="-1.05" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Volume Voided Per Micturition</title>
        <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. The mean volume per micturition was calculated by taking the sum of the urinary volumes where the volume voided was &gt; 0 and where &quot;urinary incontinence&quot; was not indicated in the patient diary, divided by the number of micturitions where the volume voided was &gt; 0 and where &quot;urinary incontinence&quot; was not indicated. Only participants who had volume voided was &gt; 0 at baseline was included in the analysis.</description>
        <time_frame>Baseline and week 4, 8, 12, 16, 28, 40, 52</time_frame>
        <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron + Solifenacin</title>
            <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron + Propiverine</title>
            <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron + Imidafenacin</title>
            <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O4">
            <title>Mirabegron + Tolterodine</title>
            <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Volume Voided Per Micturition</title>
          <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. The mean volume per micturition was calculated by taking the sum of the urinary volumes where the volume voided was &gt; 0 and where &quot;urinary incontinence&quot; was not indicated in the patient diary, divided by the number of micturitions where the volume voided was &gt; 0 and where &quot;urinary incontinence&quot; was not indicated. Only participants who had volume voided was &gt; 0 at baseline was included in the analysis.</description>
          <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="161"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.677" spread="37.450"/>
                    <measurement group_id="O2" value="30.111" spread="39.034"/>
                    <measurement group_id="O3" value="20.062" spread="30.816"/>
                    <measurement group_id="O4" value="32.854" spread="41.598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="154"/>
                    <count group_id="O2" value="148"/>
                    <count group_id="O3" value="153"/>
                    <count group_id="O4" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.328" spread="41.753"/>
                    <measurement group_id="O2" value="38.614" spread="43.030"/>
                    <measurement group_id="O3" value="23.820" spread="35.972"/>
                    <measurement group_id="O4" value="35.351" spread="35.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="146"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.452" spread="43.802"/>
                    <measurement group_id="O2" value="41.433" spread="45.910"/>
                    <measurement group_id="O3" value="27.072" spread="41.636"/>
                    <measurement group_id="O4" value="36.598" spread="46.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="144"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.952" spread="46.871"/>
                    <measurement group_id="O2" value="40.661" spread="48.257"/>
                    <measurement group_id="O3" value="24.489" spread="41.184"/>
                    <measurement group_id="O4" value="37.786" spread="44.837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="134"/>
                    <count group_id="O3" value="139"/>
                    <count group_id="O4" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.025" spread="50.761"/>
                    <measurement group_id="O2" value="41.887" spread="48.797"/>
                    <measurement group_id="O3" value="29.873" spread="48.976"/>
                    <measurement group_id="O4" value="34.823" spread="42.451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.578" spread="51.692"/>
                    <measurement group_id="O2" value="43.102" spread="52.130"/>
                    <measurement group_id="O3" value="29.826" spread="44.442"/>
                    <measurement group_id="O4" value="41.378" spread="43.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.744" spread="47.045"/>
                    <measurement group_id="O2" value="40.599" spread="45.607"/>
                    <measurement group_id="O3" value="36.653" spread="46.041"/>
                    <measurement group_id="O4" value="40.548" spread="48.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="159"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="157"/>
                    <count group_id="O4" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.004" spread="45.095"/>
                    <measurement group_id="O2" value="38.691" spread="46.429"/>
                    <measurement group_id="O3" value="32.854" spread="44.481"/>
                    <measurement group_id="O4" value="40.683" spread="46.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Number of Nocturia Episodes Per Night</title>
        <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. A nocturia episode was defined as waking at night 1 or more times to void. Night time was defined as the period between bedtime and the wake-up time the following day (micturitions at the same time as the wake-up time were excluded). The mean number of nocturia episodes per night was calculated by taking the sum of nocturia episodes in the patient diary where the variable &quot;urinated&quot; was indicated during the night time, divided by the number of nights. Only participants who had a nocturia episode at baseline was included in the analysis.</description>
        <time_frame>Baseline and week 4, 8, 12, 16, 28, 40, 52</time_frame>
        <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron + Solifenacin</title>
            <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron + Propiverine</title>
            <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron + Imidafenacin</title>
            <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O4">
            <title>Mirabegron + Tolterodine</title>
            <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Number of Nocturia Episodes Per Night</title>
          <description>Participants completed the patient diary (paper document) for 3 days immediately before each visit. A nocturia episode was defined as waking at night 1 or more times to void. Night time was defined as the period between bedtime and the wake-up time the following day (micturitions at the same time as the wake-up time were excluded). The mean number of nocturia episodes per night was calculated by taking the sum of nocturia episodes in the patient diary where the variable &quot;urinated&quot; was indicated during the night time, divided by the number of nights. Only participants who had a nocturia episode at baseline was included in the analysis.</description>
          <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
          <units>nocturia episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="143"/>
                <count group_id="O4" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="139"/>
                    <count group_id="O4" value="130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.83"/>
                    <measurement group_id="O2" value="-0.29" spread="0.73"/>
                    <measurement group_id="O3" value="-0.32" spread="1.00"/>
                    <measurement group_id="O4" value="-0.49" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="124"/>
                    <count group_id="O3" value="135"/>
                    <count group_id="O4" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.82"/>
                    <measurement group_id="O2" value="-0.37" spread="0.80"/>
                    <measurement group_id="O3" value="-0.42" spread="0.92"/>
                    <measurement group_id="O4" value="-0.44" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="122"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.96"/>
                    <measurement group_id="O2" value="-0.28" spread="0.93"/>
                    <measurement group_id="O3" value="-0.45" spread="0.99"/>
                    <measurement group_id="O4" value="-0.47" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="117"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="127"/>
                    <count group_id="O4" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.86"/>
                    <measurement group_id="O2" value="-0.37" spread="0.92"/>
                    <measurement group_id="O3" value="-0.54" spread="0.99"/>
                    <measurement group_id="O4" value="-0.50" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="121"/>
                    <count group_id="O4" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="1.00"/>
                    <measurement group_id="O2" value="-0.39" spread="0.93"/>
                    <measurement group_id="O3" value="-0.48" spread="0.97"/>
                    <measurement group_id="O4" value="-0.54" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="114"/>
                    <count group_id="O4" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.93"/>
                    <measurement group_id="O2" value="-0.45" spread="0.83"/>
                    <measurement group_id="O3" value="-0.39" spread="0.94"/>
                    <measurement group_id="O4" value="-0.54" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="110"/>
                    <count group_id="O4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.91"/>
                    <measurement group_id="O2" value="-0.44" spread="0.86"/>
                    <measurement group_id="O3" value="-0.53" spread="0.95"/>
                    <measurement group_id="O4" value="-0.50" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="139"/>
                    <count group_id="O4" value="130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.91"/>
                    <measurement group_id="O2" value="-0.38" spread="0.88"/>
                    <measurement group_id="O3" value="-0.48" spread="0.93"/>
                    <measurement group_id="O4" value="-0.48" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved Normalization of the Mean Number of Nocturia Episodes Per 24 Hours</title>
        <description>Normalization for the mean number of nocturia episodes per 24 hours was defined as no nocturia episode per 24 hours.</description>
        <time_frame>Week 52 (end of treatment)</time_frame>
        <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron + Solifenacin</title>
            <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron + Propiverine</title>
            <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron + Imidafenacin</title>
            <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O4">
            <title>Mirabegron + Tolterodine</title>
            <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved Normalization of the Mean Number of Nocturia Episodes Per 24 Hours</title>
          <description>Normalization for the mean number of nocturia episodes per 24 hours was defined as no nocturia episode per 24 hours.</description>
          <population>FAS participants with available data at each time point are included in the analysis. A last visit analysis (at the end of treatment) was performed to ensure all participants with postbaseline data were included in the analyses. Last observation carried forward (LOCF) imputation was used for the end of treatment analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="139"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postvoid Residual (PVR) Volume</title>
        <description>Measurement of PVR volume was made using either ultrasonography or urethral catheterization, provided that the same method was used for the same participant throughout the study.</description>
        <time_frame>Baseline and week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52</time_frame>
        <population>SAF</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron + Solifenacin</title>
            <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O2">
            <title>Mirabegron + Propiverine</title>
            <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O3">
            <title>Mirabegron + Imidafenacin</title>
            <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
          </group>
          <group group_id="O4">
            <title>Mirabegron + Tolterodine</title>
            <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postvoid Residual (PVR) Volume</title>
          <description>Measurement of PVR volume was made using either ultrasonography or urethral catheterization, provided that the same method was used for the same participant throughout the study.</description>
          <population>SAF</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="161"/>
                <count group_id="O4" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="157"/>
                    <count group_id="O3" value="158"/>
                    <count group_id="O4" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.07" spread="23.79"/>
                    <measurement group_id="O2" value="9.99" spread="36.05"/>
                    <measurement group_id="O3" value="6.81" spread="22.11"/>
                    <measurement group_id="O4" value="8.21" spread="28.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="148"/>
                    <count group_id="O3" value="155"/>
                    <count group_id="O4" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.68" spread="34.38"/>
                    <measurement group_id="O2" value="3.23" spread="20.40"/>
                    <measurement group_id="O3" value="5.77" spread="25.39"/>
                    <measurement group_id="O4" value="8.39" spread="29.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="146"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" spread="19.47"/>
                    <measurement group_id="O2" value="3.67" spread="20.42"/>
                    <measurement group_id="O3" value="7.19" spread="27.66"/>
                    <measurement group_id="O4" value="6.04" spread="28.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="144"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.51" spread="22.06"/>
                    <measurement group_id="O2" value="1.06" spread="18.74"/>
                    <measurement group_id="O3" value="4.04" spread="20.69"/>
                    <measurement group_id="O4" value="8.67" spread="49.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="18.01"/>
                    <measurement group_id="O2" value="3.53" spread="19.43"/>
                    <measurement group_id="O3" value="2.97" spread="19.82"/>
                    <measurement group_id="O4" value="4.68" spread="27.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="139"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.99" spread="21.14"/>
                    <measurement group_id="O2" value="4.03" spread="22.38"/>
                    <measurement group_id="O3" value="2.79" spread="16.06"/>
                    <measurement group_id="O4" value="1.46" spread="17.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="140"/>
                    <count group_id="O4" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.95" spread="19.97"/>
                    <measurement group_id="O2" value="3.87" spread="19.82"/>
                    <measurement group_id="O3" value="5.56" spread="23.90"/>
                    <measurement group_id="O4" value="5.07" spread="29.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="16.90"/>
                    <measurement group_id="O2" value="1.34" spread="17.28"/>
                    <measurement group_id="O3" value="2.19" spread="17.26"/>
                    <measurement group_id="O4" value="3.11" spread="25.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" spread="19.17"/>
                    <measurement group_id="O2" value="0.66" spread="17.96"/>
                    <measurement group_id="O3" value="2.18" spread="19.97"/>
                    <measurement group_id="O4" value="3.12" spread="17.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.03" spread="21.79"/>
                    <measurement group_id="O2" value="3.29" spread="23.24"/>
                    <measurement group_id="O3" value="5.19" spread="23.09"/>
                    <measurement group_id="O4" value="5.40" spread="35.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="16.40"/>
                    <measurement group_id="O2" value="1.03" spread="16.89"/>
                    <measurement group_id="O3" value="3.14" spread="21.56"/>
                    <measurement group_id="O4" value="0.50" spread="18.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="126"/>
                    <count group_id="O3" value="127"/>
                    <count group_id="O4" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="16.30"/>
                    <measurement group_id="O2" value="0.71" spread="17.05"/>
                    <measurement group_id="O3" value="2.22" spread="17.58"/>
                    <measurement group_id="O4" value="2.33" spread="26.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="17.51"/>
                    <measurement group_id="O2" value="4.58" spread="22.19"/>
                    <measurement group_id="O3" value="2.84" spread="19.94"/>
                    <measurement group_id="O4" value="2.02" spread="24.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="161"/>
                    <count group_id="O4" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.17" spread="39.42"/>
                    <measurement group_id="O2" value="6.83" spread="32.20"/>
                    <measurement group_id="O3" value="4.52" spread="23.51"/>
                    <measurement group_id="O4" value="5.94" spread="35.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug up to week 52</time_frame>
      <desc>Safety Analysis Set (SAF). The SAF consisted of participants who received at least 1 dose of the study drug for the treatment period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Mirabegron + Solifenacin</title>
          <description>Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.</description>
        </group>
        <group group_id="E2">
          <title>Mirabegron + Propiverine</title>
          <description>Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.</description>
        </group>
        <group group_id="E3">
          <title>Mirabegron + Imidafenacin</title>
          <description>Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.</description>
        </group>
        <group group_id="E4">
          <title>Mirabegron + Tolterodine</title>
          <description>Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disuse syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chronic hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Spinal operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Microscopic polyangiitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="97" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Residual urine volume increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi center data. Sponsor must receive a site's manuscript prior to publication for review and comment.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Astellas Pharma Inc.</organization>
      <phone>+81-3-3244-0512</phone>
      <email>astellas.resultsdisclosure@astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

